Upgrade to SI Premium - Free Trial

AC Immune SA (ACIU)

2.68 -0.08 (2.90%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU) August 24, 2026 6:55 AM - StreetInsider Form 6-K AC Immune SA For: Aug 20 August 20, 2026 7:00 AM - SEC Filing AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764 August 20, 2026 7:00 AM - StreetInsider AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 August 20, 2026 7:00 AM - StreetInsider Form 6-K AC Immune SA For: Aug 11 August 11, 2026 7:00 AM - SEC Filing AC Immune gets FDA fast track for Parkinson's drug ACI-7104 August 11, 2026 7:00 AM - StreetInsider AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) August 11, 2026 7:00 AM - StreetInsider Form 6-K AC Immune SA For: Jun 30 August 5, 2026 7:01 AM - SEC Filing AC Immune First Half 2026 Financial and Corporate Update August 5, 2026 7:00 AM - StreetInsider AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 July 7, 2026 7:00 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU) July 1, 2026 7:04 AM - StreetInsider Form 6-K AC Immune SA For: Jun 30 June 30, 2026 9:04 AM - SEC Filing AC Immune reports 12-month interim data from ACI-24 Alzheimer's trial June 30, 2026 7:00 AM - StreetInsider AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease June 30, 2026 7:00 AM - StreetInsider Full Article List